Business
Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider
SALT LAKE CITY, June 15, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced
About this update from Myriad Genetics, Inc.
[{"type":"text","content":"SALT LAKE CITY, June 15, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has received favorable coverage decisions for Prolaris® from three new commercial health plans including one of the top five national providers of health insurance. \n “We are exceptionally pleased to see continued expansion in coverage for Prolaris which will provide greater access for patients,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Approximately 60 percent of men with prostate cancer now have access to prognostic testing and we look forward to the day when every man who is facing difficult treatment decisions has access to testing through their health plan.” The first new coverage policy which can be viewed here became effective June 8, 2020, the second new coverage policy becomes effective on June 15, 2020 and the third new coverage policy which can be viewed here becomes effective on July 31, 2020. In combination, these health plans cover approximately 26 million commercial lives bringing total commercial coverage for Prolaris up to 55 million lives. About Prolaris®Prolaris is a genetic test developed by Myriad that directly measures tumor cell growth. The Prolaris test paired with both prostate-specific antigen (PSA) and Gleason provides the level of aggressiveness of a patient’s individual prostate cancer. PSA and Gleason only have the ability to identify how far the cancer has progressed thus far. However, when these are combined with a Prolaris test score, patients get an accurate assessment of how aggressively that cancer will progress over the next ten years. For more information visit: www.prolaris.com About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitionin...